Abstract | BACKGROUND: METHODS: The influence of ERα on prostate cancer progression was studied in intact male rats treated with testosterone in combination with the ERα agonist, ERA-45 for either a long-term (20-week) period or a shorter term (6-week) period. The ERβ agonist was tested in the shorter term model in intact male rats treated with testosterone in combination with the ERα agonist, ERA-45, followed by administration of the ERβ agonist, ERB-26, during the last 2 weeks. RESULTS: Treatment of rats with testosterone in combination with ERA-45 induced mild PIN lesions at 6 weeks and severe precancerous PIN lesions at 20 weeks. The ERβ agonist prevented the onset of PIN lesions at 6 weeks. Moreover, prostate epithelial cell apoptosis was increased and proliferation was decreased. CONCLUSION: These findings confirm the opposing roles ERα and ERβ play in prostate carcinogenesis and suggest a therapeutic opportunity of ERβ for treating precancerous PIN lesions.
|
Authors | D M A Attia, A G H Ederveen |
Journal | The Prostate
(Prostate)
Vol. 72
Issue 9
Pg. 1013-22
(Jun 15 2012)
ISSN: 1097-0045 [Electronic] United States |
PMID | 22025007
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2011 Wiley Periodicals, Inc. |
Chemical References |
- Estrogen Receptor alpha
- Estrogen Receptor beta
- testosterone 4-n-butylcyclohexylcarboxylic acid
- Testosterone
|
Topics |
- Adenocarcinoma
(etiology, metabolism, pathology)
- Animals
- Disease Progression
- Estrogen Receptor alpha
(agonists, physiology)
- Estrogen Receptor beta
(agonists, physiology)
- Male
- Prostate
(drug effects, pathology)
- Prostatic Neoplasms
(etiology, metabolism, pathology)
- Rats
- Rats, Wistar
- Severity of Illness Index
- Testosterone
(analogs & derivatives, pharmacology)
|